key: cord-0808355-kuccuv3a
authors: Stals, M. A.; Grootenboers, M. J.; van Guldener, C.; Kaptein, F. H.; Braken, S. J.; Chen, Q.; Chu, G.; van Driel, E. M.; Iglesias del Sol, A.; de Jonge, E.; Kant, K. M.; Pals, F.; Toorop, M. M.; Cannegieter, S. C.; Klok, F. A.; Huisman, M. V.; Coalition, Dutch COVID and Thrombosis
title: Risk of thrombotic complications in influenza versus COVID-19 hospitalized patients
date: 2020-12-19
journal: nan
DOI: 10.1101/2020.12.18.20248265
sha: f87d6610c276ddfef759f92ddf45b8cf08c4c1b5
doc_id: 808355
cord_uid: kuccuv3a

Background: Whereas accumulating studies on COVID19 patients report high incidences of thrombotic complications, large studies on clinically relevant thrombosis in patients with other respiratory tract infections are lacking. How this high risk in COVID19 patients compares to those observed in hospitalized patients with other viral pneumonias such as influenza is unknown. Objectives: To assess the incidence of venous and arterial thrombotic complications in hospitalized influenza patients as opposed to that observed in hospitalized COVID19 patients. Methods: Retrospective cohort study; we used data from Statistics Netherlands (study period: 2018) on thrombotic complications in hospitalized influenza patients. In parallel, we assessed the cumulative incidence of thrombotic complications, adjusted for competing risk of death, in patients with COVID19 in three Dutch hospitals (February 24th - April 26th 2020). Results: Of the 13.217 hospitalized influenza patients, 437 (3.3%) were diagnosed with thrombotic complications, versus 66 (11%) of the 579 hospitalized COVID19 patients. The 30 day cumulative incidence of any thrombotic complication in influenza was 11% (95%CI 9.4-12) versus 25% (95%CI 18-32) in COVID19. For venous thrombotic complications (VTE) and arterial thrombotic complications alone, these numbers were respectively 3.6% (95%CI 2.7-4.6) and 7.5% (95%CI 6.3-8.8) in influenza versus 23% (95%CI 16-29) and 4.4% (95%CI 1.9-8.8) in COVID19. Conclusions: The incidence of thrombotic complications in hospitalized influenza patients was lower than in hospitalized COVID19 patients in our study. This difference was mainly driven by a high risk of VTE complications in the COVID19 patients admitted to ICU. Remarkably, influenza patients were more often diagnosed with arterial thrombotic complications.

The clinical course of acute infections may become complicated by venous and arterial thrombotic 2 disease.[1, 2] Precipitating factors for thrombotic complications in this setting include inflammation, 3 activation of the coagulation system, immobilization, and diffuse intravascular coagulation (DIC).[1, 4 2] In light of this, international guidelines recommend pharmacological thromboprophylaxis in 5 patients with infectious diseases if they are hospitalized.

[3] 6

Respiratory viruses, including influenza, were already known to lead to a procoagulant state. [4] [5] [6] December 31 st 2018 were used to collect information on comorbidities. Information on the use of 5 pharmacological thromboprophylaxis was not available in DHD. 6 We also used data from adult COVID-19 patients admitted to the wards and ICUs of one university 7 hospital (Leiden University Medical Center, Leiden, the Netherlands) and two non-university teaching 8 hospitals (Amphia Hospital Breda and Alrijne Hospital Leiderdorp, both in the Netherlands) between 9

February 24 th and April 26 th 2020. COVID-19 was confirmed by a positive polymerase chain reaction 10 (PCR) test or considered positive in patients with a negative PCR but highly suggestive symptoms and 11 typical COVID-19 abnormalities on CT-scan of the chest (CO-RADS 4 or 5 following Dutch Radiology 12 Society[23]) with no alternative diagnosis. All COVID-19 patients had received pharmacological 13 thromboprophylaxis from admission on, according to local hospital protocols, which changed over 14 time (Appendix 3). Informed consent was obtained by an opt-out approach. This study was approved 15 by the Institutional Review Boards of the LUMC for observational studies. 16

Objectives 18

The primary objective was to assess the incidence of venous and arterial thrombotic complications in 19 hospitalized influenza patients (general ward and ICU combined) and compare this with that 20 observed in our cohort of hospitalized COVID-19 patients. 21

A diagnosis of influenza in the allocated time frame was identified in the DHD data based on 24

International Classification of Diseases (ICD) codes (Appendix 1). For those patients who had more 25 than one influenza related hospitalization, only the first hospitalization was included. In these data, a 26 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 19, 2020. ; differentiation is made between admission to a normal ward only or (temporarily) admission to an 1 ICU, but it was not possible to distinguish exact days of admittance on the general ward versus ICU. 2 Therefore, influenza patients in the DHD database were categorized as hospitalized at the ward or 3 ICU by the following definition: 1. Ward: 'hospitalizations that did not involve ICU admission' 4 (includes patients that were only admitted to the wards) and 2. ICU: 'hospitalizations that did involve 5 ICU admission' (includes patients that were admitted to the ICU at some timepoint during 6 hospitalization). Patient characteristics of included influenza patients as age, sex, and comorbidities 7 were collected. A history of comorbidities as malignancy and prior history of venous 8 thromboembolism (VTE) were screened for within 8 years before the influenza related 9

hospitalization. Prior to 2018, categorization of the hospitalization as ward and/or ICU was not 10 possible as this information was not available in the CBS database. Therefore, we studied the 11 incidence of thrombotic complications in influenza related hospitalizations during influenza seasons 12 between 2013 and 2017 as a sensitivity analysis, rather than as a main analysis. Influenza seasons 13 started from the 40 th week of one year to the 20th week of the next year. 14 The patient charts from COVID-19 patients were retrospectively scrutinized for baseline 15 characteristics and outcomes of interest. For COVID-19 we were able to strictly distinguish general 16 ward from ICU admission by exact days of admittance, but we used the influenza categorization of 17 ward and ICU in order to be consistent. 18

Outcomes 20

Information on thrombotic complications in influenza was identified by ICD codes (Appendix 1). Any 21 VTE (DVT and/or PE) or arterial thrombotic complication (ATE: ischemic stroke, myocardial infarction 22 and/or systemic arterial embolism) that occurred during the index hospitalization was regarded an 23 outcome event. The exact date of the thrombotic complication during admission was unavailable in 24 DHD. Therefore, the date halfway the hospitalization period was chosen as the date of the 25 thrombotic complication in influenza patients. 26 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 19, 2020. ; https://doi.org/10.1101/2020.12.18.20248265 doi: medRxiv preprint

In COVID-19 patients, information on thrombotic complications was identified based on scrutinizing 1 patient charts. Thrombotic complications consisted of acute pulmonary embolism (PE), deep-vein 2 thrombosis (DVT), ischemic stroke, myocardial infarction and systemic arterial embolism. No VTE 3 screening strategies were applied during this study in COVID-19 patients. Upon clinical suspicion of 4 one of the thrombotic complications, appropriate diagnostic tests were applied, i.e. computed 5 tomography pulmonary angiography (CTPA) for suspected PE and compression ultrasonography 6 (CUS) for suspected DVT, cardiac enzymes including troponin, electrocardiogram and 7 echocardiography for suspected acute coronary syndrome, and CT scan of the brain and CT 8 angiography of the carotid and intracerebral arteries for suspected ischemic stroke. 9

10 Statistical analysis 11 Patient characteristics were described using standard descriptive statistics. The analysis on the 12 comparison between influenza and COVID-19 patients, comprised the full time of hospitalization 13 (ward and ICU combined). Hospitalized influenza patients were followed from the day of hospital 14 admission (i.e., the starting date) until day of discharge, day of death or end of data collection (31th 15

December 2018), whichever came first. COVID-19 patients were followed from the day of hospital 16 admission until discharge, transfer to another hospital, until they died, or until end of data collection 17 (between April 17 and 26, 2020), whichever came first. 18

The incidence of thrombotic complications was estimated for all ICU and non-ICU patients combined, 19 patients admitted to general wards only and for patients who had been admitted to the ICU at some 20 timepoint during hospitalization (according to the DHD categorization of ward and ICU), and for all 21 thrombotic complications as well as for venous and arterial complications separately. Cumulative 22 incidences were estimated using the Kaplan-Meier method and the cumulative incidence competing 23 risk (CICR) method, to adjust for the competing risk of death. In addition, incidence rates were 24 calculated over the total follow-up period. 25

Patients 2 A total of 13.217 hospitalized influenza patients and 579 hospitalized COVID-19 patients were 3

included. Characteristics of both patient cohorts are summarized in Table 1 . Patients with influenza 4 and COVID-19 were comparable with regard to age, history of cancer, and length of hospital stay 5 (median and IQR: five days (3-10) in influenza and seven days (4-11) in COVID-19). There were more 6 male patients with COVID-19 than with influenza. 7 8 Thrombotic complications in influenza patients 9

Of the influenza patients, 437/13.217 patients (3.3%) were diagnosed with thrombotic complications, 10 of whom 126 with venous and 319 with arterial complications. The 30-day cumulative incidence of all 11 thrombotic complications, adjusted for competing risk of death, was 11% (95%CI 9.4-12) ( Table 2) . 12

The 30-day adjusted cumulative incidence for venous thrombotic complications was 3.6% (95%CI 2.7-13 4.6) and for arterial thrombotic complications 7.5% (95%CI 6.3-8. incidences for all thrombotic complications, venous thrombotic complications and arterial 20 thrombotic complications were: 8.9% (95%CI 7.5-10), 2.4% (95%CI 1.8-3.2) and 6.6% (95%CI 5.4-8.0), 21 respectively. From these ward admitted patients, 766 out of 12412 died during hospitalization 22 (6.2%). In influenza patients that had been admitted to the ICU, the adjusted 30-day cumulative 23 incidences for all thrombotic complications, venous thrombotic complications and arterial 24 thrombotic complications were: 18% (95%CI 14-23), 7.7% (95%CI 5.0-11) and 11% (95%CI 7.9-15), 25 respectively (Table 3 ). In this group of patients, 171 out of 805 died during hospital admission (21%). 26 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 19, 2020. ; https://doi.org/10.1101/2020.12.18.20248265 doi: medRxiv preprint Nevertheless, respiratory viruses, including influenza, were already known to lead to a procoagulant 1 state. [4] [5] [6] Previous studies for instance showed a transient increase in the risk of vascular 2 complications after respiratory tract infections, with a twofold increase for venous thrombotic 3 disease and an even fivefold increase for ischemic heart disease.[1, 7] Of note, in our study arterial 4 thrombotic complications, and in particular myocardial infarction, occurred more in influenza 5 patients than in COVID-19 patients. A recent study showed stroke rates quite similar to our 6 study.

[24] Strokes occurred in 0.2% in the influenza patients and in 1.6% in the COVID-19 patients 7

[24], in our study this was 0.8% in the influenza patients and 1.7% in the COVID-19 patients. 8

Furthermore, another Chinese study was recently published, which compared the incidence of VTE in 9 patients hospitalized with COVID-19 versus those hospitalized with community-acquired pneumonia 10 (CAP).

[20] Surprisingly, this study found no difference in VTE rates between CAP and COVID-19. 11

However, COVID-19 patients in this study were overall younger and had fewer comorbidities.

[20] In 12 addition, arterial thrombotic complications were not included in this study and VTE risk is known to 13 be lower in East Asians than in white Caucasians, which limits generalizing these findings to other perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 19, 2020. ; https://doi.org/10.1101/2020.12.18.20248265 doi: medRxiv preprint Therefore, both mechanisms likely play a role in the pathophysiology of COVID-19 associated 1 thrombosis and further research in this field is needed. 2 Methodological strengths of our study include the large sample size and multicenter study design. In 3 addition, VTE screening strategies have not been applied during the course of this study and 4 diagnostic tests were only performed upon clinical suspicion. Limitations of our study regarding 5 influenza data are that not all baseline patient characteristics were available, since these could only 6 be determined during a specific time period before hospital admission, and that exact dates of 7 thrombotic complications were not available. Furthermore, we do not know whether, and if so, clinically relevant confirmed thrombosis and believe that this underestimation will likely be minimal, 25 especially given this lowering threshold to suspect VTE in COVID-19. Furthermore, compared to 26 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 19, 2020. ; influenza patients, we observed a higher mortality rate in the COVID-19 ward admitted patients, 1 which indicates that the COVID-19 ward admitted patients had more severe illness than the influenza 2 ward admitted patients. Although this could (partially) explain the observed difference in thrombotic 3 risk between the ward admitted patients in both groups, this cannot explain differences found in 4 thrombotic complications between patients that had been admitted to ICU, as mortality rates in 5 these patients were quite comparable, but a large difference was found in (especially venous) 6 thrombotic complications. Altogether, the comparison between influenza and COVID-19 patients 7 could have been biased because of the difference in outcome classification and the lowered 8 threshold for diagnostic testing upon suspicion of VTE in COVID-19 patients was probably lower than 9 in influenza patients after the high incidence of thrombotic complications in COVID-19 was 10 elucidated. 11

In conclusion, this study suggests that the incidence of thrombotic complications in hospitalized 13 influenza patients is lower than in hospitalized COVID-19 patients. The difference in thrombotic 14 complications in our study was particularly driven by an exceptionally high risk for VTE in the COVID-15 19 patients that had been admitted to ICU. Remarkably, influenza patients were more often 16 diagnosed with arterial thrombotic complications than with VTE. Further studies are needed to 17 substantiate our findings and to explore explanations for this difference. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 19, 2020. ; https://doi.org/10.1101/2020.12.18.20248265 doi: medRxiv preprint 1 Gathered data and revised the manuscript critically for important intellectual content. Huisman) had full access to all the data in the study and takes responsibility for the integrity of the 12 data and the accuracy of the data analysis. The final decision to submit the manuscript was made by 13 the corresponding author on behalf of all co-authors. 14 15

Anonymous data on hospitalized COVID-19 patients as collected in this study can be made available 17 to others, on request to the corresponding author of this manuscript (MV Huisman). The request will 18 be granted after approval of a methodologically sound proposal and a signed data sharing agreement 19 is required. Data will be available after publication of the article and until five years following article 20 perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

The copyright holder for this this version posted December 19, 2020. ; https://doi.org/10.1101/2020.12.18.20248265 doi: medRxiv preprint perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 19, 2020. ; https://doi.org/10.1101/2020.12.18.20248265 doi: medRxiv preprint 

Risk of deep vein thrombosis and 2 pulmonary embolism after acute infection in a community setting

Infections and inflammatory diseases as risk 4 factors for venous thrombosis. A systematic review

Prevention of VTE in 6 nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American 7 College of Chest Physicians Evidence-Based Clinical Practice Guidelines

Review: 10 Viral infections and mechanisms of thrombosis and bleeding

Haematological manifestations in 12 patients with severe acute respiratory syndrome: retrospective analysis

Coagulation disorders in coronavirus infected patients: COVID-14 19, SARS-CoV-1, MERS-CoV and lessons from the past

Risk of myocardial 16 infarction and stroke after acute infection or vaccination

Empirical systemic 20 anticoagulation is associated with decreased venous thromboembolism in critically ill influenza A 21 H1N1 acute respiratory distress syndrome patients

Pandemic H1N1 Influenza 24 Infection and Vascular Thrombosis

Abnormal coagulation parameters are associated with poor 26 prognosis in patients with novel coronavirus pneumonia

Clinical Characteristics of 138 Hospitalized 28 Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan

High risk of 31 thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. 32 Intensive Care Med

Venous and 34 arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in 35

Pulmonary Embolism 37 in COVID-19 Patients: Awareness of an Increased Prevalence

Incidence of 39 venous thromboembolism in hospitalized patients with COVID-19

Incidence of 42 thrombotic complications in critically ill ICU patients with COVID-19

Confirmation 44 of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-45 19: An updated analysis

Thrombotic 47 complications of patients admitted to intensive care with COVID-19 at a teaching hospital in the 48 United Kingdom

Comparison of Venous Thromboembolism 1 Risks Between COVID-19 Pneumonia and Community-Acquired Pneumonia Patients

Endothelial cell infection and endotheliitis in COVID-19

Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

CO-RADS -A 8 categorical CT assessment scheme for patients with suspected COVID-19: definition and evaluation

Risk of Ischemic Stroke in 11 Patients With Coronavirus Disease 2019 (COVID-19) vs Patients With Influenza

Cardiovascular Events Associated With Influenza in Hospitalized Adults

Pulmonary post-mortem 17 findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study

Autopsy 20 Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study

Following the classification of ward (hospitalizations that did not involve ICU) and ICU (hospitalizations that 3 did involve ICU) as is done in the CBS hospitalization data

Note: All thrombotic complications: VTE and ATE together; VTE: venous thrombotic complications; ATE: arterial 5 thrombotic complications